Stock 8STN SORRENTO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Sorrento Therapeutics, Inc. Deutsche Boerse AG

Equities

8STN

US83587F2020

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sorrento Therapeutics, Inc. Emerged from Bankruptcy
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.
Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors
Combined Hearing for Disclosure Statement and Plan Approved for Sorrento Therapeutics, Inc.
Fourth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.
Third Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).
Scilex Holding's Phase 2 Trial Shows Safety, Efficacy of Treatment for Lower Back Pain
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients
Sorrento Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Bonderman's Wildcat seeks to thwart $2.9 bln Consolidated Communications deal
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRNE Stock
  4. 8STN Stock
  5. News Sorrento Therapeutics, Inc.
  6. Other languages